Alembic Pharma Peer Comparison

NSE: APLLTD | BSE: 533573

₹766.90

₹0.50 (0.07%)

As on 27-Oct-2026IST

Market cap

₹15,154 Cr

Revenue (TTM)

₹7,784 Cr

P/E Ratio

21.9

P/B Ratio

2.6

Div. Yield

1.6 %

Edit

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	15,154	30,629	31,066	26,421	25,078
Revenue (₹ Cr)	7,784	3,564	1,593	5,155	1,936
Net Profit (₹ Cr)	688.47	414.00	438.64	674.76	288.22
Net Margin (%)	8.77	11.23	27.16	11.86	14.79
RoE (%)	14.02	8.38	25.02	9.03	29.77
Price to Earnings	21.85	74.89	70.74	--	87.01
Price-To-Book	2.59	6.08	18.00	3.30	18.68

Income Statement (₹ Cr)

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	7,783.95	3,564.00	1,592.52	9,205.28	1,935.80
Total Income	7,846.79	3,686.00	1,615.23	9,449.59	1,948.58
Total Expenditure	6,614.98	2,792.00	969.32	8,195.15	1,485.56
EBITDA	1,168.97	772.00	623.20	1,010.13	450.24
Depreciation	342.49	226.00	41.96	857.51	50.83
EBIT	826.48	546.00	581.24	152.62	399.41
Interest	97.71	217.00	4.21	342.73	40.84
Other Income	62.84	122.00	22.71	244.31	12.78
Exceptional Items	-66.99	12.00	0.00	-216.88	0.00
Profit before Tax	724.62	463.00	599.74	-162.68	371.35
Provision for Tax	36.15	49.00	161.10	209.13	83.14
Profit after Tax	688.47	414.00	438.64	-371.81	288.22

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	5,674.81	4,940.00	1,857.45	8,142.24	1,288.82
Minority Interest	3.90	-5.00	0.51	0.00	0.00
Non-Current Liabilities	499.77	1,712.00	47.15	5,213.99	202.03
Current Liabilities	2,593.84	1,622.00	253.37	5,158.51	835.87
Total Liabilities	8,855.62	8,578.00	1,983.96	17,723.32	2,326.71

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	4,174.56	5,343.00	1,132.12	10,687.30	519.60
Current Assets	4,542.60	2,606.00	1,012.00	7,253.65	1,681.81
Total Assets	8,855.62	8,578.00	1,983.96	17,723.32	2,326.71
Total Debt*	1,360.85	2,125.00	26.49	5,495.48	259.37
Net Current Assets	1,948.76	984.00	758.64	2,095.14	845.94
Contingent Liabilities	160.39	768.26	17.25	95.72	19.09

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	782.73	390.00	292.17	1,652.60	205.05
Cash Flow from Investing Activities	-506.06	-241.00	-265.94	-826.03	-409.72
Cash from Financing Activities	-163.78	-54.00	4.10	-38.98	283.07
Net Cash Inflow / Outflow	112.89	95.00	30.33	787.59	78.39

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	11.74	6.79	32.42	1.24	29.22
ROE (%)	14.02	8.38	25.02	-3.83	29.77
ROA (%)	8.33	4.94	22.40	-2.14	24.77
EBIT Margin (%)	10.62	15.32	36.50	1.66	20.63
Net Margin (%)	8.77	11.23	27.16	-3.93	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	14.12	18.37	45.18	0.78	46.65
EBIT Growth (%)	7.41	252.26	115.51	-70.53	62.13
Net Profit Growth (%)	14.55	377.85	95.80	-1,383.43	89.49
EPS Growth (%)	30.14	1,001.33	63.29	-484.84	78.60
Book Value Growth (%)	9.32	13.47	26.03	0.33	144.31

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	19.67	76.86	70.74	-84.44	85.67
Price / Book Value	2.59	6.08	18.00	3.30	18.68
Dividend Yield (%)	1.56	0.00	0.07	0.00	0.10
EV/EBITDA	13.95	41.57	49.53	30.25	55.51
Market Cap (₹ Cr)	13,008.55	19,071.62	20,944.75	18,108.89	12,753.19

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	0.02	0.31	0.02	0.55	0.11
Short term debt to equity ratio	0.21	0.09	0.00	0.09	0.05
Current Ratio	1.75	1.61	3.99	1.41	2.01
Quick Ratio	0.78	1.06	2.89	0.77	1.14
Interest Coverage	8.42	3.13	143.52	0.53	10.09

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	18.84	16.50	22.50	24.48	26.28
Asset Turnover	0.94	0.43	0.81	0.53	1.66
Receivable days	36.70	58.75	88.98	78.20	40.13
Inventory Days	61.45	75.82	56.04	93.30	60.29
Payable days	157.72	186.21	99.95	226.14	232.47
Cash Conversion Cycle	-59.57	-51.64	45.07	-54.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.